title: Minimal Residual Disease by Next-Generation Sequencing: Pros and Cons.
abstract: The wealth of data recently generated highlights that minimal residual disease (MRD)-negative status can be achieved in a large proportion of patients. These studies, in addition to a meta-analysis, clearly suggest significant improvement in both event-free survival (EFS) and overall survival (OS) among those patients achieving MRD-negative status, especially with sensitivity of one cell in 1 million bone marrow cells. There is an evolving consensus that achieving MRD-negative status should become the ultimate goal of therapeutic intervention. Further future efforts should now be directed at determining how MRD status can be used to guide and personalize further therapy including type of consolidation and maintenance therapy.
authors.affiliation: From the Laboratory for Genomics in Myeloma, Institut Universitaire du Cancer and University Hospital, Centre de Recherche en Cancerologie de Toulouse, Toulouse, France.
authors.forename: Herve
authors.initials: H
authors.lastname: Avet-Loiseau
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001853:Bone Marrow / Q000276:immunology / Q000473:pathology; D018572:Disease-Free Survival; D059014:High-Throughput Nucleotide Sequencing; D006801:Humans; D007147:Immunoglobulin Light Chains / Q000235:genetics* / Q000276:immunology; D009101:Multiple Myeloma / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D009367:Neoplasm Staging; D018365:Neoplasm, Residual / Q000188:drug therapy / Q000235:genetics / Q000276:immunology / Q000473:pathology*; D011379:Prognosis
chemical_list: D007147:Immunoglobulin Light Chains